Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TROY, Mich., Oct. 06, 2016 -- DirectRx Pharmacy, a leading independent pharmacy accredited by URAC, ACHC, NABP and WBENC, is one of only a few regional, specialty pharmacies selected to dispense SAMSCA, as part of their defined pharmacy network. SAMSCA is used to treat low sodium levels or hyponatremia.
The selection process for their defined pharmacy network was based upon high performance by DirectRx in areas including time to fill prescriptions, data interpretation and efficiency of procedures. These standards have also made DirectRx the recipient of the Specialty Pharmacy (SRX) accreditation by the ACHC and the URAC validation of excellence in Specialty Pharmacy Management in recent years.
SAMSCA is manufactured by Otsuka America Pharmaceutical, Inc. for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). It is considered a specialty medication and dispensed only by pharmacies proven to provide disease specific clinical monitoring as well as patient compliance and adherence programs.
“We are pleased to be selected as a distributor of a specialty medication such as SAMSCA, which requires carefully coordinated care between the patient, pharmacy and physician,” said Amanda Berishaj PharmD, of DirectRx. “At DirectRx, there are no gaps in patient care between physician and pharmacy because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our adherence programs assure that patients are regularly measured and monitored so that each one stays on their prescribed regimen and receives the support they need throughout the course of their treatment.”
An SRX dispenses medications which target a specific population with a chronic and sometimes life-threatening disease, including Crohn’s disease/ulcerative colitis, hepatitis C, HIV/AIDS, multiple sclerosis (MS), cancer, psoriasis and rheumatoid arthritis (RA). Specialty Pharmacy includes disease specific clinical monitoring as well as patient compliance and adherence programs.
DirectRx Pharmacy, an independent, family-owned pharmacy accredited by URAC, ACHC, NABP and WBENC, is dedicated to providing patients with unparalleled, personalized pharmaceutical care for their specialty pharmacy needs. Unlike other pharmacies, DirectRx is owned and operated by certified doctors of pharmacy. The company has grown to serve more than 38 states since its inception more than two decades ago. Investments in technology help to drive the best possible patient care and deliver the most accurate data to our partners. www.DirectRx.com
CONTACT: Amanda Berishaj, PharmD, DirectRx (248) 273-0480
